Hesham Saleh Al-Sallami1, Ailsa Goulding2, Andrea Grant3, Rachael Taylor2, Nicholas Holford4, Stephen Brent Duffull5. 1. School of Pharmacy, University of Otago, PO Box 56, Dunedin, 9054, New Zealand. hesham.al-sallami@otago.ac.nz. 2. Department of Medicine, University of Otago, Dunedin, New Zealand. 3. Canterbury District Health Board, Christchurch, New Zealand. 4. Department of Pharmacology and Clinical Pharmacology, University of Auckland, Auckland, New Zealand. 5. School of Pharmacy, University of Otago, PO Box 56, Dunedin, 9054, New Zealand.
Abstract
BACKGROUND: Fat-free mass (FFM) is an important covariate for predicting drug clearance. Models for predicting FFM have been developed in adults but there is currently a paucity of mechanism-based models developed to predict FFM in children. OBJECTIVE: The aim of this study was to develop and evaluate a model to predict FFM in children. METHODS: A large dataset (496 females and 515 males) was available for model building. Subjects had a relatively wide range of age (3-29 years) and body mass index values (12-44.9 kg/m(2)). Two types of models (M1 and M2) were developed to describe FFM in children. M1 was fully empirical and based on a linear model that contained all statistically significant covariates and their interactions. M2 was a simpler model that incorporated a maturation process. M1 was developed to provide the best possible description of the data (i.e. a positive control). In addition, a published adult model (M3) was applied directly as a reference description of the data. The predictive performances of the three models were assessed by visual predictive checks and by using mean error (ME) and root mean squared error (RMSE). A test dataset (90 females and 86 males) was available for external evaluation. RESULTS: M1 consisted of nine terms with up to second-level interactions. M2 was a sigmoid hyperbolic model based on postnatal age with an asymptote at the adult prediction (M3). For the index dataset, the ME and 95 % CI for M1, M2 and M3 were 0.09 (0.03-0.16), 0.24 (0.14-0.33) and 0.29 (0.06-0.51) kg, respectively, and RMSEs were 1.12 (1.03-1.23), 1.58 (1.46-1.72) and 3.76 (3.54-3.97) kg. CONCLUSIONS: A maturation model that asymptoted to an established adult model was developed for prediction of FFM in children. This model was found to perform well in both male and female children; however, the adult model performed similarly to the maturation model for females. The ability to predict FFM in children from simple demographic measurements is expected to improve understanding of human body structure and function with direct application to pharmacokinetics.
BACKGROUND: Fat-free mass (FFM) is an important covariate for predicting drug clearance. Models for predicting FFM have been developed in adults but there is currently a paucity of mechanism-based models developed to predict FFM in children. OBJECTIVE: The aim of this study was to develop and evaluate a model to predict FFM in children. METHODS: A large dataset (496 females and 515 males) was available for model building. Subjects had a relatively wide range of age (3-29 years) and body mass index values (12-44.9 kg/m(2)). Two types of models (M1 and M2) were developed to describe FFM in children. M1 was fully empirical and based on a linear model that contained all statistically significant covariates and their interactions. M2 was a simpler model that incorporated a maturation process. M1 was developed to provide the best possible description of the data (i.e. a positive control). In addition, a published adult model (M3) was applied directly as a reference description of the data. The predictive performances of the three models were assessed by visual predictive checks and by using mean error (ME) and root mean squared error (RMSE). A test dataset (90 females and 86 males) was available for external evaluation. RESULTS: M1 consisted of nine terms with up to second-level interactions. M2 was a sigmoid hyperbolic model based on postnatal age with an asymptote at the adult prediction (M3). For the index dataset, the ME and 95 % CI for M1, M2 and M3 were 0.09 (0.03-0.16), 0.24 (0.14-0.33) and 0.29 (0.06-0.51) kg, respectively, and RMSEs were 1.12 (1.03-1.23), 1.58 (1.46-1.72) and 3.76 (3.54-3.97) kg. CONCLUSIONS: A maturation model that asymptoted to an established adult model was developed for prediction of FFM in children. This model was found to perform well in both male and female children; however, the adult model performed similarly to the maturation model for females. The ability to predict FFM in children from simple demographic measurements is expected to improve understanding of human body structure and function with direct application to pharmacokinetics.
Authors: Sarayut Janmahasatian; Stephen B Duffull; Susan Ash; Leigh C Ward; Nuala M Byrne; Bruce Green Journal: Clin Pharmacokinet Date: 2005 Impact factor: 6.447
Authors: L I Cortínez; B J Anderson; A Penna; L Olivares; H R Muñoz; N H G Holford; M M R F Struys; P Sepulveda Journal: Br J Anaesth Date: 2010-08-14 Impact factor: 9.166
Authors: B M Nielsen; M Dencker; L Ward; C Linden; O Thorsson; M K Karlsson; B L Heitmann Journal: Diabetes Obes Metab Date: 2007-07 Impact factor: 6.577
Authors: Paolo Denti; Anneke C Hesseling; Louvina E van der Laan; Anthony J Garcia-Prats; H Simon Schaaf; Tjokosela Tikiso; Lubbe Wiesner; Mine de Kock; Jana Winckler; Jennifer Norman; Helen McIlleron Journal: Antimicrob Agents Chemother Date: 2018-01-25 Impact factor: 5.191
Authors: Alanna McEneny-King; Pierre Chelle; Gary Foster; Arun Keepanasseril; Alfonso Iorio; Andrea N Edginton Journal: J Pharmacokinet Pharmacodyn Date: 2019-05-18 Impact factor: 2.745
Authors: Kevin Meesters; Robin Michelet; Reiner Mauel; Ann Raes; Jan Van Bocxlaer; Johan Vande Walle; An Vermeulen Journal: Antimicrob Agents Chemother Date: 2018-08-27 Impact factor: 5.191
Authors: Anke E Kip; María Del Mar Castro; Maria Adelaida Gomez; Alexandra Cossio; Jan H M Schellens; Jos H Beijnen; Nancy Gore Saravia; Thomas P C Dorlo Journal: J Antimicrob Chemother Date: 2018-08-01 Impact factor: 5.790